GT201000003A - "formulaciones estables de derivado de tiadiazol" - Google Patents

"formulaciones estables de derivado de tiadiazol"

Info

Publication number
GT201000003A
GT201000003A GT201000003A GT201000003A GT201000003A GT 201000003 A GT201000003 A GT 201000003A GT 201000003 A GT201000003 A GT 201000003A GT 201000003 A GT201000003 A GT 201000003A GT 201000003 A GT201000003 A GT 201000003A
Authority
GT
Guatemala
Prior art keywords
tiadiazol
derivative
stable formulations
stable
formulations
Prior art date
Application number
GT201000003A
Other languages
English (en)
Inventor
Dinesh Shyamdeo Mishra
Hong Zhuang
Hiroko Kusano
Yoshikazu Tashiro
Yosuke Watanabe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39735000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201000003A publication Critical patent/GT201000003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE PARÁMETROS DE FORMULACIÓN Y CONDICIONES DE MANUFACTURACIÓN PARA COMPOSICIONES FARMACÉUTICAS ESTABLES QUE COMPRENDEN N- N-{4
GT201000003A 2007-07-12 2010-01-07 "formulaciones estables de derivado de tiadiazol" GT201000003A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94926807P 2007-07-12 2007-07-12

Publications (1)

Publication Number Publication Date
GT201000003A true GT201000003A (es) 2012-03-13

Family

ID=39735000

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000003A GT201000003A (es) 2007-07-12 2010-01-07 "formulaciones estables de derivado de tiadiazol"

Country Status (28)

Country Link
US (1) US8222284B2 (es)
EP (1) EP2178508B1 (es)
JP (1) JP4875205B2 (es)
KR (1) KR101188036B1 (es)
CN (1) CN101730525A (es)
AR (1) AR067472A1 (es)
AU (1) AU2008275258A1 (es)
BR (1) BRPI0814039A2 (es)
CA (1) CA2694277C (es)
CL (1) CL2008001996A1 (es)
CO (1) CO6270304A2 (es)
CR (1) CR11210A (es)
DO (1) DOP2010000004A (es)
EA (1) EA016861B1 (es)
EC (1) ECSP109864A (es)
ES (1) ES2401477T3 (es)
GT (1) GT201000003A (es)
HK (1) HK1141238A1 (es)
IL (1) IL202382A0 (es)
MA (1) MA31880B1 (es)
MX (1) MX2010000468A (es)
NZ (1) NZ581791A (es)
PE (1) PE20090438A1 (es)
SV (1) SV2010003449A (es)
TN (1) TN2010000015A1 (es)
TW (1) TW200918050A (es)
UA (1) UA97672C2 (es)
WO (1) WO2009009470A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447536B1 (en) 2009-06-26 2017-12-27 Mitsubishi Electric Corporation Refrigerant compressor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847534B9 (en) 2001-12-11 2012-03-21 Kyowa Hakko Kirin Co., Ltd. Thiadiazoline derivatives for treating cancer
EP1616866B1 (en) * 2003-04-18 2011-12-14 Kyowa Hakko Kirin Co., Ltd. M-stage kinesin inhibitor
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
JPWO2006101103A1 (ja) * 2005-03-22 2008-09-04 協和醗酵工業株式会社 造血器腫瘍治療剤
KR20070113300A (ko) 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
WO2006137490A1 (ja) * 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤

Also Published As

Publication number Publication date
US20110009458A1 (en) 2011-01-13
MX2010000468A (es) 2010-04-09
EP2178508A1 (en) 2010-04-28
TW200918050A (en) 2009-05-01
IL202382A0 (en) 2010-06-30
PE20090438A1 (es) 2009-04-18
CO6270304A2 (es) 2011-04-20
CN101730525A (zh) 2010-06-09
AU2008275258A1 (en) 2009-01-15
ES2401477T3 (es) 2013-04-19
KR101188036B1 (ko) 2012-10-05
EP2178508B1 (en) 2013-02-06
TN2010000015A1 (en) 2011-09-26
HK1141238A1 (en) 2010-11-05
DOP2010000004A (es) 2010-03-15
UA97672C2 (ru) 2012-03-12
EA016861B1 (ru) 2012-08-30
CA2694277C (en) 2013-04-09
AR067472A1 (es) 2009-10-14
NZ581791A (en) 2012-03-30
US8222284B2 (en) 2012-07-17
KR20100029827A (ko) 2010-03-17
CL2008001996A1 (es) 2009-05-22
CA2694277A1 (en) 2009-01-15
CR11210A (es) 2010-06-23
MA31880B1 (fr) 2010-12-01
JP4875205B2 (ja) 2012-02-15
BRPI0814039A2 (pt) 2017-10-03
EA201070136A1 (ru) 2010-06-30
WO2009009470A1 (en) 2009-01-15
JP2010533190A (ja) 2010-10-21
ECSP109864A (es) 2010-03-31
SV2010003449A (es) 2010-08-10

Similar Documents

Publication Publication Date Title
FR22C1027I1 (fr) Formulations stabilisant et inhibant la précipitation de compositions immunogènes
BRPI0821474B8 (pt) formulação farmacêutica líquida estável
PA8719601A1 (es) Derivados de amina
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
GT200900292A (es) "inhibidores de cinasa p70 s6"
BRPI0908292A2 (pt) "métodos e composições para administração oral de exenatida"
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
SV2008003032A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
HN2012001162A (es) Triazolopiridinas
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
GT200600117A (es) Nuevos compuestos farmaceuticos
BRPI0800991A2 (pt) composiÇÕes para uso no escurecimento da pele
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
SV2009003335A (es) Formulaciones para el cancer
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
CR8929A (es) Polimorfo ii de rapamicina y usos del mismo
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
HN2008000646A (es) Antagonistas de los receptores 2 de dopamina de rapida disociacion
BRPI0907077A2 (pt) métodos e composições para administração oral de proteínas
MA32979B1 (fr) Derives aminoesterifies d'alcaloides et composition medicinale les incluant
CY1115673T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν 2-οξο-1-πυρρολιδινο παραγωγα
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
BR112015011430A2 (pt) composição para liberação imediata e prolongada
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
HN2009001268A (es) Compuestos [1,2,3] - benzotriazinona sustituido en 3 para incrementar las respuestas sinapticas glutamatergicas